With more than 15 years of experience with different international companies and products we can bring you the right insights and the right strategy to get into Latin America markets.
Latin America is an attractive pharmaceutical market, with more than 300 mi inhabitants only in the 4 major markets – Argentina, Brazil, Colombia and Mexico.
The complexity of the health system in each of these markets and how they apply to your company and products is just one of the subjects we are prepared to unfold into a strategy tailored to your needs.
Our principles
Mission
Our focus is to help pharmaceutical and biotech companies to offer their products to treat Latin America patients in the shortest time possible after they are available. We will do that by offering the best of our knowledge and the best talents to set a customized strategy to help then establishing and / or developing their business in Brazil and other Latin America countries.
Vision
We want to be the reference consultant company in market access and regulatory for pharmaceutical, biotech, devices and diagnosis companies. We want to help the companies to get faster to the market and commercialize their products in Brazil and others Latin America markets.
Values
We want to make a difference in the history of our costumer always serving them with integrity and care using our best knowledge to leverage their innovative products to improve patients lives.
INTANGIBLE VALUES
Beyond the above Brix teams are formed by hard work professionals who work always with passion and compassion.
Latin America Market
With 20 countries and a population estimated in 654 million in 2020, Latin America has a great potential to grow in pharmaceutical, biotech market. In 2019 the nominal GDP was 5.7 trillion combined with 10.5 trillion GDP PPP.
The four major pharmaceutical markets are Brazil, Mexico, Argentina and Colombia, with a highlight to Brazil which is the 8th largest market globally, with an estimated value of 25 billion in 2019.
Source: World Bank, 2020
| Rank | Country | Sales 2019 (billions, US$) | % Growth over 2018 |
|---|---|---|---|
| 1 | United States | 501.2 | 4.4 |
| 2 | China* | 94.9 | 9.1 |
| 3 | Japan | 79.0 | 2.3 |
| 4 | Germany | 51.9 | 6.7 |
| 5 | France | 35.2 | 2.9 |
| 6 | Italy | 32.9 | 3.0 |
| 7 | United Kingdom | 26.4 | 7.8 |
| 8 | Spain | 24.3 | 5.1 |
| 9 | Brazil** | 24.3 | 9.3 |
| 10 | Canada | 22.6 | 5.4 |
Notes: Prices are reported at the ex-manufacturer level (price when sold from manufacturer to wholesaler or direct to pharmacies).
* Hospital marketonly.
** Pharmacy market only. % growth, constant $.
Source: IQVIA MIDAS, MAT December 2019.
| Rank | Country | Value of Pharmaceutical Market (in billions of $) |
|---|---|---|
| 1 | Brazil | 34.25 |
| 2 | Mexico | 7.39 |
| 3 | Argentina | 4.68 |
| 4 | Central America | 1.94 |
| 5 | Chile | 1.75 |
| 6 | Colombia | 1.62 |
| 7 | Ecuador | 1.39 |
| 8 | Peru | 0.85 |
| 9 | Dominican Republic | 0.52 |
| 10 | Paraguay | 0.39 |
Source: Statista, 2020
The environment is complex and the health system differ from country to country, but as the numbers can show it is worth it. Latin America currently represents 25% of the total pharmaceutical sales.
For pharmaceutical companies, Latin America is a strong bet for future growth. Brazil will continue to be the driver with 43% of the total LA market, followed by Mexico. The successful drug manufactures will continue to look to emerging markets as a source for their growth.
Biotech companies in Latin America
Several biotech companies have made an early movement to Latin America markets, from the pioneers Genzyme, Shire, Biogen and Amgen to Biomarin, Vertex, Ferring, Takeda and others.
The earlier you start the better for the results you aim.
Services
- General strategy to enter the Latin America Markets for pharmaceutical and devices;
- Tactics: Different paths to implement the strategy and the resources needed for it;
- Assistance to plan implementation – Execution;
- Specific assistance to an issue or situation – regulatory and market access;
- Education and training – regulatory and market access basic concepts on Latin America health care markets.
Brix Team
At Brix we have previously selected a team of independent consultants with different skills and experiences that we allocate to the projects accordingly.
As soon as we get the scope of the project we talk to the consultants who we feel will fit better the project. We check their availability , willingness and costs. When we send the proposal to our clients we have the team figured out to run the project in a smooth and efficient way.
Karina Brito | Brix Consulting Founder
Karina Brito is founder and General Manager of Brix Consulting. Karina has extensive experience in Market Access and regulatory affairs in Latin America. For over 15 years, she has been responsible for establishing the strategy to companies showing to its senior management how to get the business settled in Brazil and other main Latin America countries. In some cases she was also responsible , together with a small team , to execute the strategy after the approval by the headquarters. She also coordinated teams of different sizes and level of experience. She got leadership positions in companies such as Merck Sharp & Dohme, Genzyme, Synageva/Alexion; Biogen / Bioverativ and other biotech companies. Currently she is dedicate to manage Brix Consulting ensuring that the work fully attends the needs of our clients with excellence.
Founder and General Manager
2015 Brix Consulting foundation
2016 – 2018 Bioverativ Inc – Executive Director Of Government Affairs
2014 – 2015 Synageva BioPharma Corp. – Market Access Senior Director – Latin America
2012 – 2014 BioMarin Pharmaceutical Inc. – Director Regulatory and Policy Affairs Latin America
2007 – 2011 Genzyme Inc – Sr. Director Market Access and Policy Affairs Latin America
2004 – 2007 Genzyme – Regulatory Affairs & Corporate Policy Director for Brazil
1999 – 2004 Merck Sharp & Dohme (MSD Inc) – Regulatory Affairs Manager
1998 – 1999 Merck Sharp & Dohme (MSD Inc) – Clinical Trials Manager
1997 – Merck Sharp & Dohme (MSD Inc) – Clinical Trials Monitor
Member of working groups, while working at Interfarma/Febrafarma (local pharma association), being active in this institution for 15 years (January 2000 – December 2014).
1996 – BA in Pharmacist – Universidade de São Paulo.
2001 – BA in Marketing – ESPM Escola Superior de Propaganda e Marketing
2004 – Specialization in health economics – Federal University of São Paulo.
Skills
GMP, Business Strategy, Pharmaceutics, Biopharmaceuticals, Leadership, Medical Affairs, Oncology, Regulatory Requirements, Product Launch, Regulatory Affairs, Strategic Planning, Regulatory Submissions, Negotiation, Leading People, Policy affairs, Business Planning, Sales Effectiveness, Biotechnology, Health Economics, Pharmaceutical Sales, Government Relations, Clinical Development, Market Access.
Karina Brito | Brix Consulting Founder
Karina Brito is founder and General Manager of Brix Consulting. Karina has extensive experience in Market Access and regulatory affairs in Latin America. For over 15 years, she has been responsible for establishing the strategy to companies showing to its senior management how to get the business settled in Brazil and other main Latin America countries. In some cases she was also responsible , together with a small team , to execute the strategy after the approval by the headquarters. She also coordinated teams of different sizes and level of experience. She got leadership positions in companies such as Merck Sharp & Dohme, Genzyme, Synageva/Alexion; Biogen / Bioverativ and other biotech companies. Currently she is dedicate to manage Brix Consulting ensuring that the work fully attends the needs of our clients with excellence.
Founder and General Manager
2015 Brix Consulting foundation
2016 – 2018 Bioverativ Inc – Executive Director Of Government Affairs
2014 – 2015 Synageva BioPharma Corp. – Market Access Senior Director – Latin America
2012 – 2014 BioMarin Pharmaceutical Inc. – Director Regulatory and Policy Affairs Latin America
2007 – 2011 Genzyme Inc – Sr. Director Market Access and Policy Affairs Latin America
2004 – 2007 Genzyme – Regulatory Affairs & Corporate Policy Director for Brazil
1999 – 2004 Merck Sharp & Dohme (MSD Inc) – Regulatory Affairs Manager
1998 – 1999 Merck Sharp & Dohme (MSD Inc) – Clinical Trials Manager
1997 – Merck Sharp & Dohme (MSD Inc) – Clinical Trials Monitor
Member of working groups, while working at Interfarma/Febrafarma (local pharma association), being active in this institution for 15 years (January 2000 – December 2014).
1996 – BA in Pharmacist – Universidade de São Paulo.
2001 – BA in Marketing – ESPM Escola Superior de Propaganda e Marketing
2004 – Specialization in health economics – Federal University of São Paulo.
Skills
GMP, Business Strategy, Pharmaceutics, Biopharmaceuticals, Leadership, Medical Affairs, Oncology, Regulatory Requirements, Product Launch, Regulatory Affairs, Strategic Planning, Regulatory Submissions, Negotiation, Leading People, Policy affairs, Business Planning, Sales Effectiveness, Biotechnology, Health Economics, Pharmaceutical Sales, Government Relations, Clinical Development, Market Access.
contact@brixconsulting.com.br | phone / whatsapp – +55 21 983 810 337